We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Biosimilar Draft Guidances Tackle Labeling and Interchangeables
Biosimilar Draft Guidances Tackle Labeling and Interchangeables
The FDA released two draft guidances for biosimilar manufacturers — one on labeling that focuses on prescribing information and the other on the FDA’s licensure requirements.